title: Current management of alcoholic liver disease.
abstract: Alcoholic liver disease accounts for significant economic burden with second most common cause for liver transplantation in the US. Although alcohol abstinence is most crucial, morbidity and mortality occur amongst those with continuing alcohol intake and with established end stage liver disease due to lack of specific treatment modalities to manage this disease. Patients with severe acute alcoholic hepatitis, a distinct subset of alcoholic liver disease have a potential for mortality in about 25% within about 1 month despite treatment with available specific agents such as corticosteroids and/or pentoxifylline. Hence, there is clear need for newer and better treatment options to manage these patients. In this article, potential emerging newer targets to manage this disease are discussed including intestinal decontamination, caspase inhibitors, antioxidants, and interlukins. In the background of encouraging emerging data (retrospective data from the UNOS database and data from a case matched prospective French study) on the beneficial effects of liver transplantation amongst patients with alcoholic hepatitis who are non-responders to current medical treatments, this article would also deal controversies surrounding the role and use of liver transplantation in patients with alcoholic hepatitis. Issues such as rule of 6 months of abstinence, ethical issues, and shortage of donor organs will be debated.
authors.forename: Ashwani K
authors.initials: AK
authors.lastname: Singal
authors.affiliation: Division of Gastroenterology and Hepatology, University of Alabama Birmingham, AL 35294-0012, USA. ashwanisingal.com@gmail.com.
authors.forename: Sarat C
authors.initials: SC
authors.lastname: Jampana
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000975:Antioxidants / Q000627:therapeutic use; D061945:Caspase Inhibitors / Q000627:therapeutic use; D000068800:Etanercept; D006519:Hepatitis, Alcoholic / Q000175:diagnosis / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D000069285:Infliximab; D016031:Liver Transplantation; D010431:Pentoxifylline / Q000627:therapeutic use; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D012294:Rifamycins / Q000627:therapeutic use; D000078262:Rifaximin
chemical_list: D000305:Adrenal Cortex Hormones; D000911:Antibodies, Monoclonal; D000975:Antioxidants; D061945:Caspase Inhibitors; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D012294:Rifamycins; D000069285:Infliximab; D000078262:Rifaximin; D000068800:Etanercept; D010431:Pentoxifylline